DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Pharmaceutical Lifecycle Management Strategies in 2017" report to their offering.
The report Pharmaceutical Lifecycle Management Strategies in 2017 provides a comprehensive assessment of product lifecycle (LCM) management strategies that are being implemented by pharmaceutical companies around the world.
Important challenges include pricing pressures, rising development costs, stringent regulatory and reimbursement policies, declining R&D productivity and drug patent cliffs (the immediate decline in sales after the patent expiration).
These issues, particularly the productivity gap, leave pharmaceutical companies exposed to generic and biosimilar competition, which can erode a significant percentage of their sales and market share within a short period of time. Companies risk losing up to 90% of the revenue of some of their biggest products to generic and biosimilar competition.
Key Topics Covered:
1. Introduction
2. Executive Summary
3. Introduction to Pharmaceutical Lifecycle Management Strategies
3.1 The Pharmaceutical Product Lifecycle Curve
3.2 Key Objectives of Life Cycle Management Strategies in the
3.3 What is Driving the Need for Effective Lifecycle Management
3.4 Classification and Benefits of Different Lifecycle Management
3.5 Business Opportunities Created by LCM Strategies
3.6 Factors Impacting Choice of Lifecycle Strategies
4. Pharmaceutical Lifecycle Management - Commercial Strategies
4.1 Rx-to-OTC Switch as an LCM Strategy
4.2 Geographical Expansion
4.3 Contract Research Organizations Helping Overcome Industry Challenges
4.4 Pricing and Reimbursement Strategies for LCM in Pharma
4.5 Customer Retention Programs as LCM Strategies for Pharma
4.6 Asset Transactions as an LCM Tactic
5. Regulatory and Legal Strategies
5.1 Data Exclusivity
5.2 Orphan Drug Exclusivity
5.3 Pediatric exclusivity
6. Developmental Strategies
6.1 Introduction and Classification of Developmental Strategies
6.2 Indication Expansion
6.3 Reformulation
6.4 Combination Drugs
7. Successful LCM Strategies Employed by Big Pharma: Case Studies
7.1 Pfizer
7.2 AstraZeneca
7.3 Teva
7.4 AbbVie
7.5 Roche & GSK
7.6 Cipla
7.7 Unsuccessful Implementation of LCM Strategies: Case Study
8. Patent Expiry Dates of Bestselling Pharmaceuticals 2005-2016
9. Life Cycle Management Strategies of Pipeline Products 2017
9.1 Eisai
9.2 Merck & Co
9.3 Johnson & Johnson
9.4 Takeda
9.5 AbbVie
10. Bibliography
For more information about this report visit http://www.researchandmarkets.com/research/8g74cb/pharmaceutical
